PAR Paradigm Biopharmaceuticals Limited
—Mkt Cap: —P/E: —1d ago
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treat…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value95.97M USD
Revenue (TTM)—
Gross Profit47.01K USD
Net Income (TTM)-38.93M USD
Revenue/Share—
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000PAR5
Valuation
P/E (Trailing)—
P/E (Forward)1.35
PEG—
EV/EBITDA-2.27
EV/Revenue—
P/S—
P/B40.83
EPS (TTM)-0.15
EPS (Forward)0.18
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin84.87%
Oper. Margin156513.05%
EBITDA Margin0.00%
Profit Margin-70282.28%
ROE-1623.03%
ROA-184.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.19M USD
CapEx (TTM)339.40K USD
FCF Margin—
FCF Yield—
Net Debt-5.48M USD
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity2.16
Current Ratio1.10
Quick Ratio1.07
Book Value/Sh0.0060 AUD
Cash/Share0.03 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.080 AUD
Target Range0.4200 AUD – 1.740 AUD
# Analysts2
Ownership
Shares Out.626.43M
Float530.28M
Insiders9.42%
Institutions4.62%
Technical
SMA 500.2278 AUD
SMA 2000.2260 AUD
Beta0.03
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)0
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—